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Melanoma is a very aggressive neoplasm with a propensity to undergo progression and
invasion early in its evolution.The molecular pathways underpinning invasion in melanoma
are now just beginning to be elucidated, but a clear understanding of the transition from
non-invasive to invasive melanoma cells remains elusive. Microphthalmia-associated tran-
scription factor (MITF), is thought to be a central player in melanoma biology, and it
controls many aspects of the phenotypic expression of the melanocytic lineage. How-
ever, recently the paired box transcription factor PAX3 was shown to transcriptionally
activate POU3F2/BRN2, leading to direct repression of MITF expression. Here we present
a theory to explain melanoma phenotype switching and discuss the predictions that this
theory makes. One prediction is that independent and opposing roles for MITF and PAX3
in melanoma would be expected, and we present empirical evidence supporting this: in
melanoma tissues PAX3 expression occurs independently of MITF, and PAX3 does not play
a key role in melanoma cell proliferation. Furthermore, we show that knockdown of PAX3
inhibits cell migration in a group of “lower MITF” melanoma cell lines, while knockdown
of MITF promotes cell migration in a complementary “higher MITF” group of melanoma
cell lines. Moreover, the morphological effects of knocking down PAX3 versus MITF in
melanoma cells were found to differ. While these data support the notion of independent
roles for MITF and PAX3, additional experiments are required to provide robust examina-
tion of the proposed genetic switch theory. Only upon clear delineation of the mechanisms
associated with progression and invasion of melanoma cells will successful treatments for
invasive melanoma be developed.
Keywords: melanoma, phenotype switching, paired box transcription factors, microphthalmia-associated
transcription factor, migration and invasion, pax3
INTRODUCTION
Melanoma is a malignant neoplasm of the neural crest-derived
melanocytes, the pigment-producing cells. Approximately 65% of
cutaneous melanomas are thought to arise from individual cuta-
neous melanocytes, while ∼25% arise from a pre-existing nevus.
The remaining melanomas (4–12%) appear to arise de novo with
no identifiable primary tumor. Melanoma is a very aggressive
neoplasm with a high risk of metastasis early in tumorigenesis.
Despite numerous studies, the mechanisms underlying metastasis
are complex, and a clear understanding remains elusive.
Acquisition of the ability of tumor cells to migrate repre-
sents a defining characteristic of cancer metastasis. However, cell
migration is also necessary during embryogenesis and home-
ostasis of multicellular organisms. Indeed, recent studies suggest
that melanoma cells revert to an embryonic program of gene
expression involved in neural crest cell migration to support
developmental plasticity and metastasis (1). Numerous factors are
involved in the differentiation of melanocytes, and also in the
control of cell migration.
PAX3, a member of the paired box family of genes, is a key devel-
opmental regulator of the neural crest and its derivatives, including
melanocyte progenitors (2). PAX3 is expressed in melanoma tis-
sues and cell lines, melanocyte cell lines (3, 4), and circulating
melanoma cells. Several groups (5, 6) have shown that PAX3 pro-
tein is expressed in normal skin melanocytes and melanocytic
lesions. PAX3 expression is thought to contribute to cell sur-
vival and growth (3, 4) in the melanocytic lineage. Several studies
have suggested that PAX3 expression is important in regulating
the transition from an early melanoblast derived from the neural
crest into mature melanocytes. Knockdown of PAX3 expression in
melanoma cells leads to reduced or arrested cell growth, and the
induction of apoptosis and/or senescence (3, 4).
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Microphthalmia-associated transcription factor (MITF) is
another important developmental regulator of neural crest and
its derivatives (7). MITF has been suggested to be an impor-
tant melanoma growth and survival factor (8). For instance,
FOXD3, a neural crest-associated transcription factor, is able to
repress MITF through non-canonical mechanisms, and regulate
the lineage commitment of bi-functional neural crest-derived
glial/melanocyte precursor cells into either the melanocyte or glial
lineages (9). Analysis of MITF expression in melanoma cell lines,
as well as melanoma tissues reveals marked variability in expres-
sion level, with some melanoma cell lines expressing up to 10-fold
higher levels of MITFm, a melanocyte-specific isoform of MITF,
than in other melanoma cell lines (10).
The variable levels of MITF expression in melanoma may have
important consequences. Low levels of MITF expression have been
shown to identify a small group of melanoma patients with high
mortality. Agnarsdottir and colleagues showed that patients with
melanomas where 25–75% of tumor cells stained with weak inten-
sity for MITF expression using an anti-MITF antibody were at
higher risk of death than patients with an overall strong MITF
staining intensity (11). This effect of low MITF expression level
on patient survival may be through various roles that MITF is
thought to play in cell invasion- and proliferation-associated path-
ways. High MITF levels are thought to promote cell proliferation
through the direct activation of the DIAPH1 gene, one of many
MITF target genes (12). High MITF expression has also been
shown to transcriptionally activate microRNA miR-211 expres-
sion, expressed from within the MITF target gene, TRPM1, which
results in reduction in the levels of POU3F2 (BRN2) mRNA
(13). In contrast, under conditions of low MITF expression there
is increased ROCK activity downstream of Rho, an important
mediator of cell migration (12).
High expression of POU3F2 in melanoma represseses MITF
expression (14). Moreover, POU3F2 both transcriptionally acti-
vates (including transactivation of PAX3) and represses genes
leading to enhanced cell migration/invasion and stem cell-like
characteristics (15–20). Indeed, POU3F2 is part of the phos-
phatidylinositol 3-kinase (PI3K)-PAX3-POU3F2 (BRN2) axis that
has been proposed to promote melanoma cell invasion (21). Bon-
vin and colleagues showed that inhibiting the PI3K pathway causes
down-regulation of POU3F2 and PAX3 expression, and that PAX3
directly bound to and transactivated the POU3F2 promoter, up-
regulating POU3F2 expression. These findings implicate PI3K
signaling in PAX3-dependent enhancement of POU3F2 expres-
sion and melanoma cell invasion, while simultaneously inhibiting
MITF expression (21).
A second signaling pathway that leads to cell migration also
involves the downstream activation of PAX3 expression; fibrob-
last growth factor 2 stimulates STAT3-mediated regulation of
PAX3 expression in melanocytes (22). Moreover, STAT3 activa-
tion promotes cell migration through phosphorylation of STAT3,
requiring Rho Kinase (ROCK) and JAK activity (23). Phos-
phorylated STAT3 transcriptionally activates PAX3 expression in
melanocytes, and the silencing of STAT3 or PAX3 using RNAi
was recently shown to inhibit the growth of melanoma cells,
particularly in melanoma cells that have acquired resistance to
the BRAF inhibitor, vemurafenib (24). These studies suggest that
PAX3 expression can promote melanoma progression, and that
PAX3 plays an important role in acquired resistance and recur-
rence of melanoma following treatment with tyrosine kinase
inhibitors.
Over the last 20 years a unique series of cell lines (NZM
cell lines) from metastatic melanomas (MMs) occurring in New
Zealand patients has been developed (25). To date the NZM cell
lines have been characterized for cell cycle time, drug sensitivity,
and driver gene mutation status. We recently profiled global gene
expression in a panel of 25 of these cell lines, and showed that NZM
and other melanoma cell lines could be classified into two major
groups represented by relatively lower (6/25) or higher (19/25)
MITF transcript levels. In the gene expression signature that dis-
tinguished the two groups there were 96 differentially expressed
genes, many of which are known targets of MITF, which differed
in expression in a similar fashion to MITF (26). The lower MITF
cell lines were characterized as having higher rates of migration
than higher MITF cell lines in Boyden chamber transwell assays
and scratch assays (26).
Here we extend a hypothesis that we previously suggested; that
PAX3 and MITF play independent roles in melanoma progression
(10). Moreover, we showed previously that PAX3 does not regu-
late MITF in melanoma cells (10) and we now propose a “genetic
switch” theory to explain phenotype switching (27), whereby a
PAX3-POU3F2 axis and a MITF-miR-211 axis function to neg-
atively regulate each other. This predicts that PAX3 and MITF
play distinct roles in signaling pathways that promote melanoma
progression, and also predicts additional features expected in
melanoma cells undergoing phenotype switching.
We present here several lines of experimental evidence sup-
porting the notion that PAX3 and MITF expression indeed play
independent roles in melanoma progression and cell migration.
Firstly, we show that in melanoma tissues expression of MITF and
PAX3 occur independently, and are variable from region to region,
and furthermore that the expression of PAX3 is not correlated
with Ki67 expression, a marker of cell proliferation. In addition,
we show that in melanoma cell lines with lower levels of MITF
expression, knockdown of PAX3 expression inhibits melanoma
cell migration, whereas in melanoma cell lines with higher lev-
els of MITF, knockdown of MITF enhances cell migration. In
addition we show that PAX3 promotes increased POU3F2 tran-
script levels, which then leads to repression of MITF transcript
levels. Lastly, we show that the morphological effects of knock-
ing down PAX3 versus MITF in melanoma cells differ. Taken
together with earlier published data (10), the evidence suggests
that there are distinct roles for PAX3 and MITF in melanoma
progression and melanoma cell migration, thus providing sup-
porting evidence for one of the key predictions of the genetic
switch theory.
OUTLINE OF A GENETIC SWITCH THEORY FOR THE
INVOLVEMENT OF PAX3 AND MITF AXES DURING
“PHENOTYPE SWITCHING” IN MELANOMA
The genetic switch theory is outlined in Figure 1 and embodies
the concept of two interacting signaling pathways represented by
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FIGURE 1 | A schematic of the “genetic switch” model. The
MITF-miR-211 axis is counterbalanced by the PAX3-POU3F2 axis, with high
levels of each pathway inhibiting the corresponding other pathway. “Wnt”
and “PI3K” represent one of several possible signaling pathways promoting
the activity of MITF-miR-211 axis versus the PAX3-POU3F2 axis,
respectively. High levels of the PAX3-POU3F2 axis (represented by the thick
end of the wedge) are associated with cell migration and invasion of
melanoma cells, while high levels of the MITF-miR-211 axis are associated
with proliferation and/or differentiation of melanoma cells.
PAX3-POU3F2 and MITF-miR-211, two key pathways contribut-
ing to the strength of lineage commitment and phenotypic choice
of individual melanoma cells.
In the genetic switch model we firstly note that PAX3 does
not transcriptionally activate MITF in melanoma cells. Our ear-
lier studies (10) support this notion. While in normal cells of
the melanocytic lineage during melanocyte development PAX3
transcriptionally activates MITF, it is clear there is a difference
in melanoma cells (10), and we propose this difference might
be an important feature underlying the malignant potential of
melanoma cells.
Our theory is consistent with data presented by Carreira and
colleagues (12), who proposed that MITF functions like a “rheo-
stat” with respect to cell migration. In their paper they suggested
that, depending on the expression level, MITF plays a role in
stem cell-like properties, and proliferation of melanocytes and
melanoma cells, with an effect on terminal differentiation or senes-
cence of cells at very high levels. Our genetic switch theory extends
this model, and suggests that the rheostat model may only be
half the story. In the genetic switch model we propose that the
MITF-miR-211 axis inhibits cell migration and promotes cell dif-
ferentiation in cells where the relative expression of MITF is high.
Conversely, we propose that when MITF levels are low, the expres-
sion of the PAX3-POU3F2 axis is high, and that this then promotes
cell migration and stem cell-like properties (Figure 1).
The patterns of gene expression that we, and others, have pre-
viously characterized in melanoma cell lines (26–28) might reflect
the bi-modal nature that would be predicted by the genetic switch
model. In the NZM cell lines high expression of MITF and many of
its target genes, and the low expression of another set of genes, were
found to be typical of one gene expression signature, while the low
expression of MITF and its target genes, and the high expression
of the other gene set were typical of an alternative gene expres-
sion signature. Evidence of in vivo switching between two such
alternative gene expression signatures has been suggested (27).
Moreover, expression of the “lower MITF” gene signature corre-
sponds to melanoma cells with a higher rate of migration, and
migration rates in the “higher MITF” melanoma cell type were
able to be enhanced by knocking down expression of MITF (26).
Within melanoma tissues, depending on localized exposure to
external signals or cues, signals such as PI3K or STAT3 in the exter-
nal “milieu” could activate the PAX3-POU3F2 axis, and therefore
initiate migratory stem cell-like properties in melanoma cells (21,
22). Alternatively, external Wnt signals (for instance) might acti-
vate the MITF-miR-211 axis, and so promote the expression of
adhesion molecules to anchor migrating melanoma cells in order
to colonize and proliferate in distal sites (8). Given predictions that
relatively high numbers of stem-like cells may exist in melanoma,
it may be that, in vivo, there is a relatively high frequency of the
conversion rate from the proliferative phenotype to the migra-
tory “stem cell-like” phenotype in melanoma cells compared to
the reverse conversion rate.
Furthermore, accumulating evidence supports two models of
how melanoma cells move, a cytoskeletal model of dynamic actin
microfilaments, and a membrane flow model of plasma mem-
brane deposition and recycling (23). In the former of these mod-
els it has been shown that STAT3 signaling plays an important
role, which again provides supporting evidence for the role of a
PAX3-POU3F2 axis in promoting cell migration.
Aside from what we have discussed above, several predic-
tions arise from the proposed genetic switch theory. The first
of these is that MITF and PAX3 should both have independent
roles and expression patterns in melanoma cells. The second
prediction is that the MITF-miR-211 axis will prevail precisely
when the PAX3-POU3F2 axis wanes, and vice versa. This predic-
tion will need to be investigated in in vitro and in vivo models.
In vitro, it is predicted that MITF and/or miR-211 expression
would be enhanced in melanoma cells with knockdown of the
PAX3-POU3F2 axis, and that PAX3 and/or POU3F2 expression
will be enhanced in melanoma with knockdown of MITF-miR-
211 axis. We have already obtained preliminary evidence that the
knockdown of MITF leads to increased POU3F2 mRNA levels
in NZM12 melanoma cells (He, Jeffs et al., unpublished data).
The third prediction is that during periods of enhanced cell
migration, melanoma cells would be under the influence of the
PAX3-POU3F2 axis, and that melanoma cells not enhanced in
migration would be under the influence of the MITF-miR-211
axis. The fourth prediction is that high activity of the PAX3-
POU3F2 axis would lead to stem cell-like features, with reduced
pigmentation, reduced mitotic activity of melanoma cells, and
enhanced resistance to drugs that inhibit proliferation, while
high activity of the MITF-miR-211 axis would lead to more
strongly differentiated melanocytic features, enhanced pigmen-
tation, and enhanced mitotic activity, with reduced resistance
to drugs that inhibit proliferation. A fifth prediction that per-
haps arises from all the above predictions, but is important
nevertheless in translating to patients, is that the use of treat-
ments in patients targeting MITF might result in enhancement of
melanoma metastasis.
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RESULTS
PAX3 AND MITF EXPRESSION VARY IN THEIR RELATIVE INTENSITY IN
DIFFERENT REGIONS OF MELANOMA
Several experimental approaches were used to investigate whether
PAX3 and MITF expression and function were independent in
melanoma cells and tissues. In the first approach we used dual
label immunofluorescence to compare the relative expression of
PAX3 and MITF in adjacent regions within the same melanoma
tissue section. To do this PAX3 and MITF were immunolabeled
with different fluorophores, and the captured immunofluorescent
images merged. The relative saturation (intensity) of the signals in
the merged image were then visualized (Figure 2). Relative levels
of MITF expression in normal skin melanocytes (observed as a sin-
gle layer of cells in the basal layer of the epidermis – see Figure 2)
seemed to vary in relation to each other more than the variation
in PAX3 expression (Figures 2A,B). In melanoma the expression
of MITF appeared to be generally more intense relative to PAX3,
and tended to involve cells immediately underlying the epidermal
surface (“Top dermis,”Figure 2B). Cells that expressed lower levels
of MITF relative to PAX3 were often located deeper below the epi-
dermal surface of the tissue (“Deep dermis,” Figure 2B). This was
also observed in dysplastic nevi (not shown). We show two repre-
sentative melanoma tissues (MM and lentigo maligna melanoma)
where cells more distal to the epidermal surface showed a lower
intensity of MITF expression relative to PAX3 expression, and a
change in color saturation was observed in melanoma cells more
distal to the epidermal surface compared to cells immediately
below the epidermal surface (Figures 2A,B). These data suggest
that variations in the relative levels of PAX3 and MITF protein
occur from region to region in melanoma tissues. Such variations
in the expression of these factors could impact on the invasive
behavior of melanoma cells.
PAX3 IS RELATIVELY INFREQUENTLY CO-EXPRESSED WITH Ki67 IN
MELANOMA TISSUE
We next investigated whether expression of PAX3 is associated with
loss of growth control in melanoma, which is a role that MITF
has been implicated (8), as might be expected if PAX3 and MITF
were to function in the same or similar pathways. We investigated
whether PAX3 expression is co-localized with the cell proliferation
marker, Ki67, scoring cells that were positive in immunofluores-
cence for both PAX3 and Ki67 as a percentage of the total number
of PAX3-positive cells. Expression of PAX3 practically never co-
localized with Ki67 expression in nevi (Figure 3), suggesting that
the expression of PAX3 was in general not associated with prolifer-
ation in nevi. Co-localization of Ki67 with PAX3 was also relatively
infrequent in melanomas including superficial spreading, lentigo
maligna melanoma and nodular melanoma, and MMs, with an
average of only ∼20% of cells co-expressing Ki67 and PAX3 in
the latter (Figure 3). The observation that the expression of PAX3
does not markedly overlap with Ki67-positive melanoma cells (as
the majority of PAX3-positive cells were Ki67-negative) suggests
that PAX3 expression is not associated with cell proliferation in
melanoma. The observed low frequency (∼20%) of incidental
co-expression of PAX3 and Ki67 could simply reflect progressive
deregulation of growth control in melanoma cells, as marked by
Ki67 expression.
RNAi-MEDIATED KNOCKDOWN OF PAX3 GENE EXPRESSION LEADS TO
REDUCED POU3F2 mRNA LEVELS AND MIGRATORY BEHAVIOR AND
INCREASED MITF mRNA LEVELS IN MELANOMA CELL LINES
We previously characterized a panel of melanoma cell lines for
expression levels of MITF and PAX3, and cell migratory behav-
iors (10, 26). Four melanoma cell lines chosen from this panel
were transfected with siRNAs against PAX3 to determine whether
migration of the melanoma cells depended on PAX3 expression.
Knockdown of PAX3 in NZM9 and NZM40, characterized to
have lower levels of MITF expression and a high cell migra-
tion potential (10, 26), led to a significant decrease in migra-
tion rate (p< 0.001, Figure 4), whereas the knockdown of PAX3
in NZM6 and NZM15 (characterized to have higher levels of
MITF expression and a low migration potential) did not cause
a significant change in the migration rates in transwell assays.
In contrast, knockdown of MITF in NZM6 and NZM15 cell
lines caused an average of ∼4-fold increase in migration rate in
the transwell assays (p< 0.001, Figure 4), whereas in the highly
motile NZM9 and NZM40 cell lines there was no significant
change in migration potential observed with MITF knockdown
(Figure 4).
In two different NZM melanoma cell lines (NZM11 and
NZM12), one of which has previously been characterized to be
a “lower MITF” cell line (NZM11), and the other cell line previ-
ously characterized as a “higher MITF” cell line (NZM12) (10, 26),
the knockdown of PAX3 expression resulted in decreased levels of
POU3F2 transcripts in both cell lines (Figure 5). In the NZM12
cell line there was a concomitant increase inMITF transcript levels,
consistent with the proposed genetic switch hypothesis (Figure 5).
An increase in the levels of both MITF mRNA and protein in
NZM12, NZM11, NZM9, and NZM15 cell lines in response to
PAX3 knockdown has also previously been reported (10). Inter-
estingly, in two other “lower MITF” expressing melanoma cell
lines (i.e., NZM9 and NZM40) there were undetectable levels
of POU3F2 expression. It is possible that these “lower MITF”
melanoma cell lines have an alternative pathway to suppress MITF
that does not involve POU3F2 expression.
These data suggest that relatively higher expression of PAX3
compared to MITF in “lower MITF” cell lines may facilitate cell
migration in those melanoma cell lines, while relatively higher
expression of MITF to PAX3 in “higher MITF” cell lines may
inhibit cell migration.
RNAi-MEDIATED KNOCKDOWN OF PAX3 OR MITF GENE EXPRESSION
LEADS TO DIFFERENT PHENOTYPIC MORPHOLOGIES IN MELANOMA
CELLS
The knockdown of either PAX3 or MITF expression had dif-
ferent effects on the morphology of NZM15 cells in culture
(Figure 6). Knockdown of MITF in NZM15 cells led to cells
with a fibroblast-like spindle-cell phenotype with dendrites pro-
truding from the cells. In contrast, knockdown of PAX3 led to
the cells acquiring an epithelial-like rounded phenotype with few
dendrites.
DISCUSSION
The data presented here are consistent with and extend our pre-
vious work, in which we showed that melanoma cell lines with
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FIGURE 2 | PAX3 and MITF expression vary in their relative intensity
in different regions of melanoma. (A) The figure shows
photomicrographs of dual immunofluorescent staining of MITF expression
(green label), PAX3 expression (red label), DAPI nuclear staining (blue
label), and a merged image in normal skin, metastatic melanoma (Primary
MM), and Lentigo maligna melanoma. The scale bar, which varies in length
on the images, represents 50µm. (B) Higher magnification
photomicrographs taken from the merged image in (A) of the Primary and
Lentigo maligna melanomas show in greater detail the difference in the
relative immunofluorescence color intensity of MITF labeling versus PAX3
labeling in the tumor cells immediately below the skin surface (“Top
dermis”) versus cells located deeper in the tumor (“Deep dermis”). Below
the panels is shown a color intensity scale, with one end representing
relatively strong MITF intensity, and the opposite end representing
relatively strong PAX3 intensity. The scale bar in the bottom right image is
for all the panels and represents 25µm.
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FIGURE 3 | Dual immunofluorescent staining of Ki67 and PAX3 in
benign and malignant melanocytic lesions. (A) Graph showing the
percentage of PAX3 and Ki67 double positive (dp) cells as a percentage of
the total number of PAX3-positive cells for superficial spreading melanoma
(SSM), lentigo maligna melanoma and nodular melanoma (LMM & NM), and
metastatic melanoma (MM), ***p<0.001. (B) Photomicrographs showing
the results of immunofluorescent staining for PAX3, Ki67, and merged
images for an intradermal nevus (IN), superficial spreading melanoma
(SSM), nodular melanoma (NM), and metastatic melanoma (MM). The scale
bar, which varies in length on the images, represents 50µm.
low levels of MITF expression (NZM9, NZM11, NZM22, NZM40,
and NZM52) have higher (∼23-fold) migratory potential than
melanoma cell lines with high MITF expression levels (NZM6,
NZM12, NZM15, NZM42, NZM45). The latter cell lines have a low
migratory potential using scratch and transwell (Boyden chamber)
migration assays (26). Furthermore, we previously showed that
knockdown of MITF expression in NZM6 and NZM15 melanoma
cell lines led to an almost 4-fold increase in the migration rates of
the cells (26).
Our results suggest that PAX3 might play a role in melanoma
cell invasion (rather than in proliferation), and our data predict
that the effect of increased signaling through the PAX3/POU3F2
pathway on cell migration would be most pronounced in
melanoma cells in vivo where the MITF expression levels are rel-
atively low. In addition, reduced MITF expression levels would
occur when POU3F2 expression is elevated, and this would also
correspond to instances in vivo in melanoma tissues when pig-
ment production is reduced (19). In contrast, in melanoma cells
in vivo where the MITF expression is high there is likely to be a
minimal role of the PAX3-POU3F2 axis in promoting melanoma
cell invasion.
We reported previously that PAX3 is extensively expressed in
melanocytes, nevi and melanoma tissues (6), and that expression
levels of PAX3 and MITF are highly variable in melanoma cell
lines, and are not concordant with each other, especially com-
paring individual melanoma cells in culture (10). We have also
previously reported that PAX3 does not transcriptionally activate
MITF in melanoma cells (10), an observation contrary to that out-
lined in a number of contemporary melanoma research papers.
Current belief has it that in melanoma, PAX3 transcriptionally
activates MITF and therefore functions in an epistatic relation-
ship with MITF. This is a notion held by many in the melanoma
field, primarily because in neural crest development and dur-
ing melanocyte differentiation PAX3 transcriptionally activates
MITF [reviewed in Ref. (7, 8)]. Our earlier investigations (10)
are, to our knowledge, the only comprehensive investigations
systematically addressing this notion, demonstrating that PAX3
does not transcriptionally activate MITF in melanoma cells. Fur-
ther, as suggested in Figure 2, the relative expression levels of
PAX3 and MITF are variable in different regions of melanoma
tissue, which is not inconsistent with observations of transient
changes in pigment production and of POU3F2 expression asso-
ciated with melanoma dissemination (19). Indeed, amongst sev-
eral melanoma cell lines that we have examined previously, we
observed relatively large fluctuations in MITFm expression, and
the variations in PAX3 expression level were not as great as
MITFm (10).
Our RNAi data in Figure 4 suggest that PAX3 and MITF
expression contribute in distinct ways to cell migration, lead-
ing to the suggestion that it is the relative strengths of signals
in the PAX3-POU3F2 axis versus the MITF-miR-211 axis that
define the strength of lineage commitment in melanoma cells,
and the migratory behavior of the melanoma cells. This latter
interpretation could be related to the mechanisms involved in
phenotype switching of melanoma cells, where melanoma cells
are induced to de-differentiate from a relatively strongly differ-
entiated and proliferative melanoma cell lineage to a more stem
cell-like phenotype with reduced proliferation and enhanced cell
migration (10, 17, 29).
In conclusion, here we have presented new evidence that PAX3
and MITF expression have independent and opposing effects in
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FIGURE 4 | Knockdown of PAX3 or MITF results in differential effects on
the migration of melanoma cell lines in vitro. siRNA-mediated knockdown
of PAX3 inhibits the migration of melanoma cells expressing lower levels of
MITF (green bars), but not melanoma cells expressing higher levels of MITF
(red bars). Conversely, siRNA-mediated knockdown of MITF does not
enhance the migration of melanoma cells expressing lower levels of MITF
(green bars), but does enhance the migration of melanoma cells expressing
high levels of MITF (red bars). **p<0.001.
melanoma. In line with these data we are proposing a genetic
switch theory as a working model to guide future experimental
approaches investigating the mechanisms underlying melanoma
progression, and the acquisition of resistance and invasiveness. As
more work is carried out to test the predictions made from the
genetic switch theory, this in turn should lead to a better under-
standing of mechanisms associated with melanoma progression.
Developing a clear description of the mechanisms in melanoma
associated with key molecular pathways and phenotype switch-
ing is highly likely to be important for the successful treatment of
invasive melanoma.
MATERIALS AND METHODS
HUMAN TISSUES, CELL LINES, AND CELL CULTURE
Normal human skin, human nevus, and melanoma tissues,
which were formalin-fixed and embedded in paraffin blocks were
obtained from Dunedin hospital. Approval for the use of the
archival formalin-fixed paraffin-embedded tissues in research was
from the New Zealand Multi-Region Ethics Committee. A panel
of metastatic human melanoma cell lines, NZM1-NZM48, estab-
lished in culture from human MM tissue explants (25) were
grown at 37°C in a low oxygen (5% O2, 5% CO2) humidified
atmosphere in ITS (Roche, Penzberg, Germany) medium compris-
ing α-modified minimal essential medium (Invitrogen, Carlsbad,
CA, USA) insulin (10µg/mL), transferrin (10µg/mL), selenite
(10 ng/mL), and 10% fetal bovine serum (FBS) as previously
described (25). These cell lines were then subsequently cultured
in 5% CO2 and 95% air humidified atmosphere in ITS DMEM
medium and 10% FBS.
IMMUNOHISTOCHEMICAL AND IMMUNOFLUORESCENCE STAINING
Tissue sections were cut at 4µm thickness. Antigen retrieval was
performed by heating in 10 mM Tris, 1 mM EDTA buffer, at pH
9, for 30 min. Non-specific antigen reactivity in the sections was
blocked by incubation in 1× BSA (ImmSolv LLC, Seattle, DC,
USA) for 30 min at room temperature, followed by incubation
with PAX3 antibody [Developmental Studies Hybridoma Bank
(DSHB, Iowa, IA, USA)] diluted 1:50 or MITF antibody (Invitro-
gen, Clone C5+D5) diluted 1:100 in 0.3×BSA/PBS buffer and
incubated at 4°C overnight. The slides were then washed and incu-
bated with horse anti-mouse biotin conjugated antibody and Vec-
tastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA).
DAB was used as the substrate chromagen and hematoxylin as the
counterstain. For dual immunofluorescence staining, mouse anti-
PAX3 antibody (DSHB) and rabbit anti-MITF antibody (Atlas
Antibodies, 1:50) were co-incubated for 2 h at room temperature,
then followed by washing, and secondary antibodies (goat anti-
mouse – Alexa fluor-568 and goat anti-rabbit-Alexa fluor-488,
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FIGURE 5 | Knockdown of PAX3 results in a decrease of POU3F2 and an
increase of MITF gene transcript levels in melanoma cell lines in vitro.
Transcript levels of PAX3, POU3F2, and MITF mRNA were examined by
RT-qPCR in NZM12, and in NZM11 (PAX3 and POU3F2 only) melanoma cell
lines following RNAi treatment of the cell lines with either siRNAs against
luciferase (siGL2) as a negative control, or against PAX3 (siPAX3). The
results were calculated as the fold difference in transcript level relative to
the level of the housekeeping gene GNB2L1, normalized to the siGL2 data.
FIGURE 6 | Knockdown of PAX3 or MITF results in differential
morphological effects in NZM15 melanoma cells. NZM15 melanoma
cells were grown in media without any transfection (MC), or transfected
with siRNA to luciferase (siGL2) as a non-targeting control, siRNA to MITF
(siMITF), or siRNA to PAX3 (siPAX3) and then stained after 48 h with
β-tubulin antibody.
both from Invitrogen Molecular Probes, 1:1000 dilutions) incu-
bation for 1 h. The β-tubulin antibody (clone E7) was purchased
from DSHB, and the secondary antibody was goat anti-mouse –
Alexa fluor-568. The cell fixation and staining processes were the
same as described previously (10). Negative control incubations
using the same secondary antibody, but omitting the primary
antibodies were also carried out and showed negative staining
Table 1 | PCR primers and amplicon sizes.
Gene Primer sequence (5′→3′′) Amplicon (bp)
PAX3 F ACGCGGTCTGTGATCGAAACA 126
R TCTCGCTTTCCTCTGCCTCCTT
MITF F GAGCACTGGCCAAAGAGAGG 82
R ATGCGGTCATTTATGTTAAATCTTCTTC
POU3F2 F TTTCCTCAAATGCCCCAAG 108
R TTTCTGTCTCCTGTTACAAAACCA
GNB2L1 F CACAACGGGCACCACCAC 138
R CACACACCCAGGGTATTCCAT
as expected. Images were captured with using a Zeiss Axioplan
(Germany) microscope, Diagnostic digital camera (Model# 9.4
Slider-6) and Spot software (USA). Fluorescent light source was
from EXFO X-Cite 120.
siRNA TRANSFECTIONS
Cells were cultured in 5% CO2 and 95% air humidified atmos-
phere in ITS DMEM medium and 10% FBS prior to and during
PAX3-siRNA, and MITF-siRNA treatments. A reverse transfec-
tion technique was used to deliver siRNAs to melanoma cell
lines according to the manufacturer’s instructions (Lipofectamine
RNAiMAX; Invitrogen, cat. no. 13778-075). Briefly, 1µl of Lipo-
fectamine RNAiMAX and 6 pmol of siRNA were used for each
well of 24-well-plate, in 100µl of OPTI MEM I media and 500µl
of cells (6× 104/mL). PAX3-siRNA from Ambion (ID#: 215907):
sense, GCCGCAUCCUGAGAAGUAAtt; antisense, UUACUU-
CUCAGGAUGCGGCtg. MITF-siRNA from Ambion (ID#: 3816):
sense, GGACAAUCACAACCUGAUUtt; antisense, AAUCAGGU-
UGUGAUUGUCCtt. An siRNA against Luciferase (from Dharma-
con Research Inc.) was used as negative control scramble siRNA,
mRNA target sequence AACGUACGCGGAAUACUUCGA.
QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTION-PCR ANALYSIS
Total RNA was extracted from cell lines and subject to RT-qPCR
analysis as previously described (10), with the exception that a
Roche Lightcycler was used for amplification and analysis. The
primer sequences and the amplicon sizes of the PCR products are
shown in Table 1.
TRANSWELL MIGRATION ASSAYS
Transwell migration assays were carried out using 1× 105 cells
seeded into transwell inserts with 8µm micropore filters (Becton
Dickinson) as previously described (26).
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